Iron and cancer: more ore to be mined

[1]  Rosanne Raso,et al.  Changing a paradigm. , 2015, Nursing management.

[2]  R. Saha,et al.  Microbial siderophores: a mini review , 2013, Journal of basic microbiology.

[3]  J. Connor,et al.  Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages , 2013, Breast Cancer Research and Treatment.

[4]  C. Butterfield,et al.  Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  D. Richardson,et al.  The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action , 2013, Molecular Pharmacology.

[6]  M. Grever,et al.  A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. , 2012, International journal of radiation oncology, biology, physics.

[7]  S. Sang,et al.  Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced Hamster Cheek Pouch Carcinogenesis by a 5-Lipoxygenase Inhibitor, Garcinol , 2012, Nutrition and cancer.

[8]  S. Stewart,et al.  DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network , 2012, Cell cycle.

[9]  C. Denkert,et al.  Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer , 2012, PloS one.

[10]  M. Tsao,et al.  Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma , 2012, PloS one.

[11]  Colm E. Nestor,et al.  Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome , 2012, Genome Biology.

[12]  Y. Zhang,et al.  NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. , 2012, Cancer epidemiology.

[13]  Elizabeta Nemeth,et al.  Hepcidin and iron homeostasis. , 2012, Biochimica et biophysica acta.

[14]  J. Kaplan,et al.  Ferroportin-mediated iron transport: expression and regulation. , 2012, Biochimica et biophysica acta.

[15]  Marta A. Uzarska,et al.  The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. , 2012, Biochimica et biophysica acta.

[16]  D. Richardson,et al.  A new strategy for the treatment of pancreatic cancer: Novel thiosemicarbazone iron chelators that up-regulate the iron-regulated metastasis suppressor, NDRG1 , 2012 .

[17]  E. McGhee,et al.  Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. , 2012, Cell reports.

[18]  Y. Kanai,et al.  Fenton Reaction Induced Cancer in Wild Type Rats Recapitulates Genomic Alterations Observed in Human Cancer , 2012, PloS one.

[19]  M. Campone,et al.  Validation of tumor‐associated macrophage ferritin light chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC study , 2012, International journal of cancer.

[20]  A. Vashisht,et al.  MMS19 Assembles Iron-Sulfur Proteins Required for DNA Metabolism and Genomic Integrity , 2012, Science.

[21]  F. Torti,et al.  Ferritin Blocks Inhibitory Effects of Two-Chain High Molecular Weight Kininogen (HKa) on Adhesion and Survival Signaling in Endothelial Cells , 2012, PloS one.

[22]  L. Lund,et al.  No Effect of NGAL/lipocalin-2 on Aggressiveness of Cancer in the MMTV-PyMT/FVB/N Mouse Model for Breast Cancer , 2012, PloS one.

[23]  X. Jing,et al.  Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for transferrin-receptor-overexpressing cancer models. , 2012, Molecular pharmaceutics.

[24]  D. Richardson,et al.  Iron chelators for the treatment of cancer. , 2012, Current medicinal chemistry.

[25]  R Laubenbacher,et al.  The core control system of intracellular iron homeostasis: a mathematical model. , 2012, Journal of theoretical biology.

[26]  J. Greenson,et al.  Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis. , 2012, Cancer research.

[27]  M. Zheng,et al.  The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1) , 2012, The Journal of Biological Chemistry.

[28]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[29]  R. Sinha,et al.  Heme iron from meat and risk of adenocarcinoma of the esophagus and stomach , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[30]  Y. Yen,et al.  A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study , 2012, Cancer Chemotherapy and Pharmacology.

[31]  M. Dizdaroglu,et al.  Mechanisms of free radical-induced damage to DNA , 2012, Free radical research.

[32]  D. Richardson,et al.  Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti‐tumour efficacy , 2012, British journal of pharmacology.

[33]  Brian Keith,et al.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.

[34]  J. Wrana,et al.  Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. , 2011, Cancer research.

[35]  Kaixian Chen,et al.  Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies , 2011, Clinical Cancer Research.

[36]  Suzy V. Torti,et al.  An iron regulatory gene signature predicts outcome in breast cancer. , 2011, Cancer research.

[37]  D. Carson,et al.  Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model. , 2011, In vivo.

[38]  R. Lill,et al.  Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes , 2011, Nature chemical biology.

[39]  D. Jacobs,et al.  Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. , 2011, Archives of internal medicine.

[40]  D. Richardson,et al.  Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer , 2011, Molecular Pharmacology.

[41]  R. Sougrat,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[42]  G. E. Carpagnano,et al.  Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes? , 2011, European journal of clinical investigation.

[43]  M. Willingham,et al.  Iron Uptake Mediated by Binding of H-Ferritin to the TIM-2 Receptor in Mouse Cells , 2011, PloS one.

[44]  S. Terai,et al.  Deferoxamine for advanced hepatocellular carcinoma. , 2011, The New England journal of medicine.

[45]  E. Toone,et al.  Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer , 2011, Oncogene.

[46]  V. Hower,et al.  Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress. , 2011, Free radical biology & medicine.

[47]  Wei Zhang,et al.  NGAL Expression Is Elevated in Both Colorectal Adenoma–Carcinoma Sequence and Cancer Progression and Enhances Tumorigenesis in Xenograft Mouse Models , 2011, Clinical Cancer Research.

[48]  Masao Tanaka,et al.  Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. , 2011, Anticancer research.

[49]  J. Voorhees,et al.  Receptor-type Protein Tyrosine Phosphatase β (RPTP-β) Directly Dephosphorylates and Regulates Hepatocyte Growth Factor Receptor (HGFR/Met) Function* , 2011, The Journal of Biological Chemistry.

[50]  J. Connor,et al.  Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. , 2011, Cancer research.

[51]  D. Richardson,et al.  Cellular Iron Depletion Stimulates the JNK and p38 MAPK Signaling Transduction Pathways, Dissociation of ASK1-Thioredoxin, and Activation of ASK1* , 2011, The Journal of Biological Chemistry.

[52]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[53]  Yun Wu,et al.  Relationships of lipocalin 2 with breast tumorigenesis and metastasis , 2011, Journal of cellular physiology.

[54]  O. Kovalchuk,et al.  Role of ferritin alterations in human breast cancer cells , 2011, Breast Cancer Research and Treatment.

[55]  Xiuzhen Han,et al.  The antitumor activity of the fungicide ciclopirox , 2010, International journal of cancer.

[56]  Elizabeta Nemeth,et al.  In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. , 2010, Blood.

[57]  P. Apostoli,et al.  Polarization dictates iron handling by inflammatory and alternatively activated macrophages , 2010, Haematologica.

[58]  W. Criekinge,et al.  The N‐myc downstream regulated gene (NDRG) family: diverse functions, multiple applications , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  H. Glatt,et al.  The Friedreich's ataxia protein frataxin modulates DNA base excision repair in prokaryotes and mammals , 2010, The Biochemical journal.

[60]  M. Hentze,et al.  Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. , 2010, Blood.

[61]  M. Willingham,et al.  Ferroportin and iron regulation in breast cancer progression and prognosis. , 2010, Science translational medicine.

[62]  F. Torti,et al.  Serum ferritin: Past, present and future. , 2010, Biochimica et biophysica acta.

[63]  A. Pietrangelo.  Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. , 2010, Gastroenterology.

[64]  J. Marks,et al.  Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. , 2010, Cancer research.

[65]  Michael R. Green,et al.  A Mammalian Siderophore Synthesized by an Enzyme with a Bacterial Homolog Involved in Enterobactin Production , 2010, Cell.

[66]  R. Strong,et al.  Iron Traffics in Circulation Bound to a Siderocalin (Ngal)-Catechol Complex , 2010, Nature chemical biology.

[67]  L. Larocca,et al.  Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  C. Ouzounis,et al.  Tumorigenic Properties of Iron Regulatory Protein 2 (IRP2) Mediated by Its Specific 73-Amino Acids Insert , 2010, PloS one.

[69]  D. English,et al.  HFE C282Y homozygotes are at increased risk of breast and colorectal cancer , 2010, Hepatology.

[70]  R. Elliott,et al.  Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. , 2010, Anticancer research.

[71]  D. Girelli,et al.  Differential regulation of iron homeostasis during human macrophage polarized activation , 2010, European journal of immunology.

[72]  W. Seaman,et al.  Binding and uptake of H-ferritin are mediated by human transferrin receptor-1 , 2010, Proceedings of the National Academy of Sciences.

[73]  T. Mak,et al.  Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis , 2010, Proceedings of the National Academy of Sciences.

[74]  G. Semenza.  HIF-1: upstream and downstream of cancer metabolism. , 2010, Current opinion in genetics & development.

[75]  F. Torti,et al.  Synthetic and natural iron chelators: therapeutic potential and clinical use. , 2009, Future medicinal chemistry.

[76]  V. Hower,et al.  A systems biology view of cancer. , 2009, Biochimica et biophysica acta.

[77]  Yate-Ching Yuan,et al.  2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase . , 2009, Biochemistry.

[78]  J. Dick,et al.  Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. , 2009, Blood.

[79]  D. Gottschling,et al.  Mitochondrial Dysfunction Leads to Nuclear Genome Instability via an Iron-Sulfur Cluster Defect , 2009, Cell.

[80]  R. Crichton.  Iron Metabolism: From Molecular Mechanisms to Clinical Consequences , 2009 .

[81]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1 , 2009, Science.

[82]  C. Peyssonnaux,et al.  HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. , 2009, The Journal of clinical investigation.

[83]  R. Nelson.  Iron and colorectal cancer risk: human studies. , 2009, Nutrition reviews.

[84]  V. Hower,et al.  A general map of iron metabolism and tissue-specific subnetworks. , 2009, Molecular bioSystems.

[85]  D. Watters,et al.  Ferritin functions as a proinflammatory cytokine via iron‐independent protein kinase C zeta/nuclear factor kappaB–regulated signaling in rat hepatic stellate cells , 2009, Hepatology.

[86]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[87]  F. Gonzalez,et al.  Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. , 2009, Cell metabolism.

[88]  R. D'Agostino,et al.  Regulatory effects of ferritin on angiogenesis , 2009, Proceedings of the National Academy of Sciences.

[89]  R. D'Agostino,et al.  Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. , 2009, Blood.

[90]  F. Torti,et al.  Post-transcriptional Modulation of Iron Homeostasis during p53-dependent Growth Arrest* , 2008, Journal of Biological Chemistry.

[91]  Stephen C. West,et al.  RTEL1 Maintains Genomic Stability by Suppressing Homologous Recombination , 2008, Cell.

[92]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[93]  A. Kristal,et al.  Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. , 2008, Carcinogenesis.

[94]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[95]  M. Melbye,et al.  Donation frequency, iron loss, and risk of cancer among blood donors. , 2008, Journal of the National Cancer Institute.

[96]  B. Goh,et al.  A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells , 2008, Investigational New Drugs.

[97]  A. Friedl,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer , 2008, Breast Cancer Research and Treatment.

[98]  R. Planalp,et al.  Curcumin: From ancient medicine to current clinical trials , 2008, Cellular and Molecular Life Sciences.

[99]  B. Cooper,et al.  A role for iron in Wnt signalling , 2008, Oncogene.

[100]  S. Cross,et al.  Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma , 2008, Clinical Cancer Research.

[101]  A. Miller,et al.  Dietary iron and haem iron intake and risk of endometrial cancer: a prospective cohort study , 2007, British Journal of Cancer.

[102]  S. Toyokuni,et al.  Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway. , 2007, The American journal of pathology.

[103]  M. Thun,et al.  Genetic Variability in Iron-Related Oxidative Stress Pathways (Nrf2, NQ01, NOS3, and HO-1), Iron Intake, and Risk of Postmenopausal Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[104]  B. Lönnerdal.  Trace element transport in the mammary gland. , 2007, Annual review of nutrition.

[105]  V. Nizet,et al.  Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). , 2007, The Journal of clinical investigation.

[106]  M. Knutson.  Steap proteins: implications for iron and copper metabolism. , 2007, Nutrition reviews.

[107]  L. Zacharski,et al.  Iron Stimulates Urokinase Plasminogen Activator Expression and Activates NF-kappa B in Human Prostate Cancer Cells , 2007, Nutrition and cancer.

[108]  D. Richardson,et al.  Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. , 2007, Blood.

[109]  Mayka Sanchez,et al.  Iron-regulatory proteins limit hypoxia-inducible factor-2α expression in iron deficiency , 2007, Nature Structural &Molecular Biology.

[110]  E. Eisenhauer,et al.  Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161) , 2007, Investigational New Drugs.

[111]  M. Kivimäki,et al.  Does personality predict mortality? Results from the GAZEL French prospective cohort study. , 2007, International journal of epidemiology.

[112]  C. Fillebeen,et al.  Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. , 2006, Carcinogenesis.

[113]  S. Toyokuni,et al.  Deletion and single nucleotide substitution at G:C in the kidney of gpt delta transgenic mice after ferric nitrilotriacetate treatment , 2006, Cancer science.

[114]  D. Richardson,et al.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.

[115]  M. F. White,et al.  The DNA repair helicases XPD and FancJ have essential iron-sulfur domains. , 2006, Molecular cell.

[116]  Chin‐Chung Wu,et al.  Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. , 2006, Journal of medicinal chemistry.

[117]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[118]  S. Hong,et al.  Ectopic expression of neutrophil gelatinase‐associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells , 2006, International journal of cancer.

[119]  G. Berx,et al.  Modulation of iron transport proteins in human colorectal carcinogenesis , 2006, Gut.

[120]  R. Planalp,et al.  Iron chelation in the biological activity of curcumin. , 2006, Free radical biology & medicine.

[121]  T. Schulz,et al.  Induction of Oxidative Metabolism by Mitochondrial Frataxin Inhibits Cancer Growth , 2006, Journal of Biological Chemistry.

[122]  T. Schulz,et al.  Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. , 2005, Human molecular genetics.

[123]  M. Mark.  Pathogenesis, diagnosis and treatment , 2005 .

[124]  M. Brechbiel,et al.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. , 2005, Blood.

[125]  J. J. Sharp,et al.  Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells , 2005, Nature Genetics.

[126]  Li Yan,et al.  The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients , 2005, Clinical Cancer Research.

[127]  Jerry Kaplan,et al.  Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.

[128]  Francesca Zazzeroni,et al.  Ferritin Heavy Chain Upregulation by NF-κB Inhibits TNFα-Induced Apoptosis by Suppressing Reactive Oxygen Species , 2004, Cell.

[129]  J. Snyder,et al.  Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. , 2004, Bioorganic & medicinal chemistry.

[130]  J. Blumberg,et al.  Dietary Iron Promotes Azoxymethane-Induced Colon Tumors in Mice , 2004, Nutrition and cancer.

[131]  M. Fishman,et al.  A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer , 2004, Cancer Chemotherapy and Pharmacology.

[132]  P. Arosio,et al.  Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. , 2004, Blood.

[133]  J. Freudenheim,et al.  Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. , 2004, Annals of epidemiology.

[134]  G. Gao,et al.  Crystal Structure of Human Pirin , 2004, Journal of Biological Chemistry.

[135]  Yate-Ching Yuan,et al.  In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase , 2004, Cancer Research.

[136]  R. Hultcrantz,et al.  Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. , 2003, Gastroenterology.

[137]  S. Bingham,et al.  Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. , 2003, Cancer research.

[138]  S. Mathew,et al.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.

[139]  M. Hentze,et al.  Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: Implications for regulation and cellular function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[140]  M. Willingham,et al.  Activation of Caspase Pathways during Iron Chelator-mediated Apoptosis* , 2002, The Journal of Biological Chemistry.

[141]  J. Liao,et al.  Dietary Iron Supplementation Enhances DSS-Induced Colitis and Associated Colorectal Carcinoma Development in Mice , 2002, Digestive Diseases and Sciences.

[142]  Y. Gruenbaum,et al.  Ferritin expression modulates cell cycle dynamics and cell responsiveness to H-ras-induced growth via expansion of the labile iron pool. , 2002, The Biochemical journal.

[143]  C. Kahn,et al.  Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro. , 2002, Human molecular genetics.

[144]  S. Toyokuni,et al.  Specific allelic loss of p16 (INK4A) tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. , 2002, The American journal of pathology.

[145]  H. Tsukamoto.  Iron regulation of hepatic macrophage TNFα expression , 2002 .

[146]  N. Milman,et al.  Clinically overt hereditary hemochromatosis in Denmark 1948–1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients , 2001, Annals of Hematology.

[147]  M. Willingham,et al.  p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. , 2001, Carcinogenesis.

[148]  Y. Gruenbaum,et al.  Repression of ferritin expression modulates cell responsiveness to H-ras-induced growth. , 2001, Biochemical Society transactions.

[149]  N. Haites,et al.  Breast cancer in two sisters with Friedreich's ataxia. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[150]  M. Mattioli,et al.  Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron‐related chronic liver disease , 2001, Hepatology.

[151]  A. Albertini,et al.  Overexpression of Wild Type and Mutated Human Ferritin H-chain in HeLa Cells , 2000, The Journal of Biological Chemistry.

[152]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[153]  B. Mazumder,et al.  Role of Hypoxia-inducible Factor-1 in Transcriptional Activation of Ceruloplasmin by Iron Deficiency* , 2000, The Journal of Biological Chemistry.

[154]  Yusuke Nakamura,et al.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.

[155]  C. Lok,et al.  Identification of a Hypoxia Response Element in the Transferrin Receptor Gene* , 1999, The Journal of Biological Chemistry.

[156]  L. Bianchi,et al.  Transferrin Receptor Induction by Hypoxia , 1999, The Journal of Biological Chemistry.

[157]  Kou-Juey Wu,et al.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.

[158]  M. Brechbiel,et al.  Tumor cell cytotoxicity of a novel metal chelator. , 1998, Blood.

[159]  M. Pandolfo,et al.  Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. , 1997, Science.

[160]  G. Semenza,et al.  Hypoxia-inducible Factor-1 Mediates Transcriptional Activation of the Heme Oxygenase-1 Gene in Response to Hypoxia* , 1997, The Journal of Biological Chemistry.

[161]  K. Kulp,et al.  Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. , 1996, Experimental cell research.

[162]  T. Stephenson,et al.  Gastric carcinoma in siblings with Friedreich's ataxia. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[163]  A. Houghton,et al.  Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[164]  E. Feskens,et al.  Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. , 1995, International journal of epidemiology.

[165]  C. Beaumont,et al.  Role for NF-κB in the Regulation of Ferritin H by Tumor Necrosis Factor-α (*) , 1995, The Journal of Biological Chemistry.

[166]  J. Olsen,et al.  Cancer risk following primary hemochromatosis: A population‐based cohort study in Denmark , 1995, International journal of cancer.

[167]  S. Toyokuni,et al.  DNA base modifications in renal chromatin of wistar rats treated with a renal carcinogen, ferric nitrilotriacetate , 1994, International journal of cancer.

[168]  B. Graubard,et al.  Moderate elevation of body iron level and increased risk of cancer occurrence and death , 1994, International journal of cancer.

[169]  A. Reunanen,et al.  Body iron stores and risk of cancer , 1994, International journal of cancer.

[170]  G. Semenza,et al.  Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. , 1993, Blood.

[171]  T. Saika,et al.  Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts. , 1993, The Journal of biological chemistry.

[172]  E. Gelfand,et al.  Definition of the roles for iron and essential fatty acids in cell cycle progression of normal human T lymphocytes. , 1993, Experimental cell research.

[173]  M. Stahlhut,et al.  Iron enhances tumor growth. Observation on spontaneous mammary tumors in mice , 1991, Cancer.

[174]  B. Halliwell,et al.  Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. , 1991, Archives of biochemistry and biophysics.

[175]  C. Hann,et al.  Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines , 1990, Hepatology.

[176]  K. Myambo,et al.  The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. , 1988, The Journal of biological chemistry.

[177]  M. Stahlhut,et al.  Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. , 1988, Cancer research.

[178]  S. Kawanishi,et al.  Hydroxyl radical production and human DNA damage induced by ferric nitrilotriacetate and hydrogen peroxide. , 1987, Cancer research.

[179]  S. Okada,et al.  Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. , 1987, Cancer research.

[180]  S. Okada,et al.  Nephrotoxicity of ferric nitrilotriacetate. An electron-microscopic and metabolic study. , 1986, The American journal of pathology.

[181]  J. Mendelsohn,et al.  Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. , 1986, Cancer research.

[182]  A. Sonnenberg,et al.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. , 1985, The New England journal of medicine.

[183]  V. Siskind,et al.  Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. , 1985, Journal of the National Cancer Institute.

[184]  A. Gräslund,et al.  Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. , 1983, The Journal of biological chemistry.

[185]  A. Gräslund,et al.  Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. , 1983, Biochemical and biophysical research communications.

[186]  G. Psathas,et al.  Human Studies , 1980 .

[187]  H. Richmond.  Induction of Sarcoma in the Rat by Iron—Dextran Complex , 1959, British medical journal.

[188]  J. Campbell.  Effects of Precipitated Silica and of Iron Oxide on the Incidence of Primary Lung Tumours in Mice , 1940, British medical journal.

[189]  Campbell Ja.  Effects of Precipitated Silica and of Iron Oxide on the Incidence of Primary Lung Tumours in Mice. , 1940 .

[190]  R. Crichton.  Comprar Inorganic Biochemistry of Iron Metabolism: From Molecular Mechanisms to Clinical Consequences | Robert Crichton | 9780470010280 | Wiley , 2009 .

[191]  M. Hentze,et al.  Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. , 2008, Cell metabolism.

[192]  D. Stewart,et al.  Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells , 2008, Angiogenesis.

[193]  J. Miklossy,et al.  Iron withholding: a defense against disease. , 2008, Journal of Alzheimer's disease : JAD.

[194]  K. Robien,et al.  the Iowa Women's Health Study , 2008 .

[195]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[196]  Francesca Zazzeroni,et al.  Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. , 2004, Cell.

[197]  C. Raggi,et al.  Mini review , 2004 .

[198]  H. Tsukamoto.  Iron regulation of hepatic macrophage TNFalpha expression. , 2002, Free radical biology & medicine.

[199]  X. H. Wang,et al.  In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. , 1987, Blood.

[200]  S. Okada,et al.  Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitrilotriacetate complexes in rats. , 1986, Journal of the National Cancer Institute.

[201]  E. Weinberg.  Iron withholding: a defense against infection and neoplasia. , 1984, Physiological reviews.

[202]  N. Andrews,et al.  ASH 50th Anniversary Reviews (34 articles) , 2022 .

[203]  N. Dubin.  Mathematical Model , 2022 .